Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCUCLEAR vs PREFRIN-A
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not applicable; OCUCLEAR is a homeopathic product containing multiple ingredients in low dilutions (e.g., Euphrasia officinalis, Calendula officinalis, etc.). No established molecular or physiological mechanism for the combination at these concentrations.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Relief of minor eye irritations due to dryness, allergies, or overuse
Temporary relief of nasal congestion,Fever reduction,Mild to moderate pain relief
1 drop in each eye twice daily (morning and evening) as ophthalmic solution.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
Terminal elimination half-life is approximately 20-24 hours; allows once-daily dosing in most patients, but may be prolonged in renal impairment.
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Not applicable; active ingredients are present in extremely low concentrations (typically 6X to 30X potency) and are not expected to undergo significant systemic metabolism.
Phenylephrine undergoes extensive first-pass metabolism by monoamine oxidase (MAO) in the liver and gut; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to a hepatotoxic metabolite NAPQI.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minor (<10%).
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Plasma protein binding is approximately 99%, primarily to albumin.
Phenylephrine: 50-60% bound to albumin and alpha-1-acid glycoprotein; Antazoline: ~20% bound to albumin.
Volume of distribution is 0.1-0.3 L/kg, indicating minimal extravascular distribution and high intravascular retention.
Phenylephrine: Vd ~0.5 L/kg (distributes primarily into extracellular fluid); Antazoline: Vd ~2 L/kg (extensive tissue distribution).
Oral bioavailability is 90-100%, consistent with nearly complete absorption.
Ocular: <1% systemic bioavailability after topical administration; intranasal: 10-20% systemic bioavailability; oral: 2-5% due to first-pass metabolism.
No dosage adjustment required for renal impairment; however, use caution in severe renal disease (Cr Cl <30 m L/min) due to potential systemic absorption.
No dosage adjustment required for renal impairment.
No formal studies in hepatic impairment; use caution in Child-Pugh class C (severe) due to possible increased systemic exposure.
No dosage adjustment required for hepatic impairment.
Safety and efficacy not established; use not recommended in pediatric patients under 18 years.
Children ≥6 years: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily. Children <6 years: not recommended.
No specific dose adjustment; monitor for increased intraocular pressure or systemic effects due to potential age-related changes in clearance.
Use with caution due to increased risk of systemic absorption and adverse effects; consider lowest effective dose and frequency.
None
None.
Do not use if solution changes color or becomes cloudy. Do not touch dropper tip to any surface to avoid contamination. Contact lens wearers should remove lenses before instillation and wait 10 minutes before reinserting. If symptoms persist or worsen, consult a physician.
Avoid use in patients with hypertension, hyperthyroidism, diabetes, or cardiovascular disease. Risk of hepatotoxicity with acetaminophen overdose. Do not exceed recommended dose. Avoid concurrent use with MAO inhibitors.
Known hypersensitivity to any component. Not for use in patients with acute eye infection, glaucoma, or other serious eye conditions.
Hypersensitivity to phenylephrine, acetaminophen, or any excipients. Severe hypertension or coronary artery disease. Concomitant use or within 14 days of MAO inhibitors.
No specific food interactions known for ophthalmic ketorolac. However, systemic NSAIDs can interact with alcohol (increased GI bleeding risk), but this is negligible with ocular use.
Avoid alcohol and products containing caffeine or other stimulants as they may increase the risk of cardiovascular adverse effects. No specific food restrictions beyond maintaining hydration.
No adequate studies in pregnant women. Animal studies not available. Risk cannot be ruled out. Use only if potential benefit justifies risk.
Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction and reduced placental perfusion; risk of fetal hypoxia in third trimester. Pyrilamine: Class B in pregnancy; animal studies show no fetal harm. Avoid in first trimester due to theoretical risk of vasoconstriction. Use only if benefit outweighs risk.
Unknown if excreted in human milk. Caution advised. M/P ratio not available.
Phenylephrine: minimal excretion in breast milk; M/P ratio unknown. Pyrilamine: not known if excreted. Antihistamines may cause drowsiness or irritability in infant. Avoid if possible due to lack of safety data. Consider alternative with more data.
No dose adjustment recommendations due to lack of data.
No specific dose adjustment recommendations due to lack of pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Consider alternative agents if possible.
Ocuclear (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Use with caution in patients with bleeding disorders or those on anticoagulants due to increased risk of ocular bleeding. Monitor for corneal epithelial effects with prolonged use. Contraindicated in patients with aspirin allergy or NSAID hypersensitivity.
Prefrin-A combines phenylephrine (alpha-1 agonist vasoconstrictor) with pyrilamine (first-generation antihistamine). Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, or narrow-angle glaucoma. Avoid in patients taking MAO inhibitors or within 14 days of discontinuation. Rebound congestion can occur with prolonged use (>3 days). Monitor for CNS depression or paradoxical excitation in children.
Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Wash hands before and after use.,Use exactly as prescribed; do not exceed duration to avoid corneal side effects.,May cause transient stinging or blurred vision upon instillation.,Report any eye pain, vision changes, or signs of infection (redness, discharge) promptly.
Use exactly as directed; do not use for more than 3 days to avoid rebound congestion.,Avoid driving or operating machinery if drowsiness occurs, especially when combined with alcohol or other CNS depressants.,Do not use if you have high blood pressure, heart disease, thyroid problems, diabetes, or glaucoma unless directed by a doctor.,Discontinue use and consult a doctor if symptoms persist or worsen, or if you experience severe dizziness, headache, or irregular heartbeat.,Store at room temperature away from moisture and heat. Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCUCLEAR vs PREFRIN-A, answered by our medical review team.
OCUCLEAR is a Ophthalmic decongestant that works by Not applicable; OCUCLEAR is a homeopathic product containing multiple ingredients in low dilutions (e.g., Euphrasia officinalis, Calendula officinalis, etc.). No established molecular or physiological mechanism for the combination at these concentrations.. PREFRIN-A is a Ophthalmic Decongestant/Antihistamine Combination that works by PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCUCLEAR and PREFRIN-A depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCUCLEAR is: 1 drop in each eye twice daily (morning and evening) as ophthalmic solution.. The standard adult dose of PREFRIN-A is: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCUCLEAR and PREFRIN-A in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCUCLEAR is classified as Category C. No adequate studies in pregnant women. Animal studies not available. Risk cannot be ruled out. Use only if potential benefit justifies risk.. PREFRIN-A is classified as Category C. Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.